Kevin N Sheth1, Mercy H Mazurek1, Matthew M Yuen1, Bradley A Cahn1, Jill T Shah1, Adrienne Ward2, Jennifer A Kim1, Emily J Gilmore1, Guido J Falcone1, Nils Petersen1, Kevin T Gobeske1, Firas Kaddouh1, David Y Hwang1, Joseph Schindler1, Lauren Sansing1, Charles Matouk3, Jonathan Rothberg4,5, Gordon Sze6, Jonathan Siner7, Matthew S Rosen8, Serena Spudich9, W Taylor Kimberly10. 1. Department of Neurology, Yale University School of Medicine, New Haven, Connecticut. 2. Neuroscience Intensive Care Unit, Yale New Haven Hospital, New Haven, Connecticut. 3. Department of Neurosurgery, Yale School of Medicine, New Haven, Connecticut. 4. Department of Genetics, Yale University School of Medicine, New Haven, Connecticut. 5. Hyperfine Research Inc, Guilford, Connecticut. 6. Department of Radiology, Yale University School of Medicine, New Haven, Connecticut. 7. Division of Pulmonology and Sleep Medicine, Department of Medicine, Yale University School of Medicine, New Haven, Connecticut. 8. Athinoula A. Martinos Center for Biomedical Imaging, Massachusetts General Hospital, Charlestown. 9. Division of Neurology Infections & Global Neurology, Department of Neurology, Yale University School of Medicine, New Haven, Connecticut. 10. Division of Neurocritical Care, Department of Neurology, Massachusetts General Hospital, Boston.
Abstract
IMPORTANCE: Neuroimaging is a key step in the clinical evaluation of brain injury. Conventional magnetic resonance imaging (MRI) systems operate at high-strength magnetic fields (1.5-3 T) that require strict, access-controlled environments. Limited access to timely neuroimaging remains a key structural barrier to effectively monitor the occurrence and progression of neurological injury in intensive care settings. Recent advances in low-field MRI technology have allowed for the acquisition of clinically meaningful imaging outside of radiology suites and in the presence of ferromagnetic materials at the bedside. OBJECTIVE: To perform an assessment of brain injury in critically ill patients in intensive care unit settings, using a portable, low-field MRI device at the bedside. DESIGN, SETTING, AND PARTICIPANTS: This was a prospective, single-center cohort study of 50 patients admitted to the neuroscience or coronavirus disease 2019 (COVID-19) intensive care units at Yale New Haven Hospital in New Haven, Connecticut, from October 30, 2019, to May 20, 2020. Patients were eligible if they presented with neurological injury or alteration, no contraindications for conventional MRI, and a body habitus not exceeding the scanner's 30-cm vertical opening. Diagnosis of COVID-19 was determined by positive severe acute respiratory syndrome coronavirus 2 polymerase chain reaction nasopharyngeal swab result. EXPOSURES: Portable MRI in an intensive care unit room. MAIN OUTCOMES AND MEASURES: Demographic, clinical, radiological, and treatment data were collected and analyzed. Brain imaging findings are described. RESULTS: Point-of-care MRI examinations were performed on 50 patients (16 women [32%]; mean [SD] age, 59 [12] years [range, 20-89 years]). Patients presented with ischemic stroke (n = 9), hemorrhagic stroke (n = 12), subarachnoid hemorrhage (n = 2), traumatic brain injury (n = 3), brain tumor (n = 4), and COVID-19 with altered mental status (n = 20). Examinations were acquired at a median of 5 (range, 0-37) days after intensive care unit admission. Diagnostic-grade T1-weighted, T2-weighted, T2 fluid-attenuated inversion recovery, and diffusion-weighted imaging sequences were obtained for 37, 48, 45, and 32 patients, respectively. Neuroimaging findings were detected in 29 of 30 patients who did not have COVID-19 (97%), and 8 of 20 patients with COVID-19 (40%) demonstrated abnormalities. There were no adverse events or complications during deployment of the portable MRI or scanning in an intensive care unit room. CONCLUSIONS AND RELEVANCE: This single-center series of patients with critical illness in an intensive care setting demonstrated the feasibility of low-field, portable MRI. These findings demonstrate the potential role of portable MRI to obtain neuroimaging in complex clinical care settings.
IMPORTANCE: Neuroimaging is a key step in the clinical evaluation of brain injury. Conventional magnetic resonance imaging (MRI) systems operate at high-strength magnetic fields (1.5-3 T) that require strict, access-controlled environments. Limited access to timely neuroimaging remains a key structural barrier to effectively monitor the occurrence and progression of neurological injury in intensive care settings. Recent advances in low-field MRI technology have allowed for the acquisition of clinically meaningful imaging outside of radiology suites and in the presence of ferromagnetic materials at the bedside. OBJECTIVE: To perform an assessment of brain injury in critically ill patients in intensive care unit settings, using a portable, low-field MRI device at the bedside. DESIGN, SETTING, AND PARTICIPANTS: This was a prospective, single-center cohort study of 50 patients admitted to the neuroscience or coronavirus disease 2019 (COVID-19) intensive care units at Yale New Haven Hospital in New Haven, Connecticut, from October 30, 2019, to May 20, 2020. Patients were eligible if they presented with neurological injury or alteration, no contraindications for conventional MRI, and a body habitus not exceeding the scanner's 30-cm vertical opening. Diagnosis of COVID-19 was determined by positive severe acute respiratory syndrome coronavirus 2 polymerase chain reaction nasopharyngeal swab result. EXPOSURES: Portable MRI in an intensive care unit room. MAIN OUTCOMES AND MEASURES: Demographic, clinical, radiological, and treatment data were collected and analyzed. Brain imaging findings are described. RESULTS: Point-of-care MRI examinations were performed on 50 patients (16 women [32%]; mean [SD] age, 59 [12] years [range, 20-89 years]). Patients presented with ischemic stroke (n = 9), hemorrhagic stroke (n = 12), subarachnoid hemorrhage (n = 2), traumatic brain injury (n = 3), brain tumor (n = 4), and COVID-19 with altered mental status (n = 20). Examinations were acquired at a median of 5 (range, 0-37) days after intensive care unit admission. Diagnostic-grade T1-weighted, T2-weighted, T2 fluid-attenuated inversion recovery, and diffusion-weighted imaging sequences were obtained for 37, 48, 45, and 32 patients, respectively. Neuroimaging findings were detected in 29 of 30 patients who did not have COVID-19 (97%), and 8 of 20 patients with COVID-19 (40%) demonstrated abnormalities. There were no adverse events or complications during deployment of the portable MRI or scanning in an intensive care unit room. CONCLUSIONS AND RELEVANCE: This single-center series of patients with critical illness in an intensive care setting demonstrated the feasibility of low-field, portable MRI. These findings demonstrate the potential role of portable MRI to obtain neuroimaging in complex clinical care settings.
Authors: Hedvig Hricak; David J Brenner; S James Adelstein; Donald P Frush; Eric J Hall; Roger W Howell; Cynthia H McCollough; Fred A Mettler; Mark S Pearce; Orhan H Suleiman; James H Thrall; Louis K Wagner Journal: Radiology Date: 2010-12-16 Impact factor: 11.105
Authors: Mathieu Sarracanie; Cristen D LaPierre; Najat Salameh; David E J Waddington; Thomas Witzel; Matthew S Rosen Journal: Sci Rep Date: 2015-10-15 Impact factor: 4.379
Authors: Zsuzsanna Varga; Andreas J Flammer; Peter Steiger; Martina Haberecker; Rea Andermatt; Annelies S Zinkernagel; Mandeep R Mehra; Reto A Schuepbach; Frank Ruschitzka; Holger Moch Journal: Lancet Date: 2020-04-21 Impact factor: 79.321
Authors: Sai Abitha Srinivas; Stephen F Cauley; Jason P Stockmann; Charlotte R Sappo; Christopher E Vaughn; Lawrence L Wald; William A Grissom; Clarissa Z Cooley Journal: Magn Reson Med Date: 2021-09-04 Impact factor: 4.668
Authors: Chengyue Wu; Guillermo Lorenzo; David A Hormuth; Ernesto A B F Lima; Kalina P Slavkova; Julie C DiCarlo; John Virostko; Caleb M Phillips; Debra Patt; Caroline Chung; Thomas E Yankeelov Journal: Biophys Rev (Melville) Date: 2022-05-17
Authors: Matthew M Yuen; Anjali M Prabhat; Mercy H Mazurek; Isha R Chavva; Anna Crawford; Bradley A Cahn; Rachel Beekman; Jennifer A Kim; Kevin T Gobeske; Nils H Petersen; Guido J Falcone; Emily J Gilmore; David Y Hwang; Adam S Jasne; Hardik Amin; Richa Sharma; Charles Matouk; Adrienne Ward; Joseph Schindler; Lauren Sansing; Adam de Havenon; Ani Aydin; Charles Wira; Gordon Sze; Matthew S Rosen; W Taylor Kimberly; Kevin N Sheth Journal: Sci Adv Date: 2022-04-20 Impact factor: 14.957